These findings have several important implications: (1) they emphasize that despite an immune system potentially compromised by immunosenescence, older patients retain the ability to mount clinically relevant anti-cancer responses against Her2, which could be exploited in immunotherapy; (2) they suggest that one mechanism dampening beneficial anti-TAA responses is the presence of suppressive cells, which could be targeted therapeutically to enhance anti-cancer activity. The gene discussed is ERBB2; the disease is cancer.